ECULIZUMAB (Soliris) prior authorization at EmblemHealth
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
EmblemHealth requires Complement Inhibitor prior-authorization documentation for ECULIZUMAB (Soliris): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
EmblemHealth reviews ECULIZUMAB (Soliris) prior authorizations against its medical policy for Complement Inhibitor. EmblemHealth-specific context: NY-based; operates HIP (HMO) and GHI (PPO) brands; ~3M members. Administers the NYC municipal employee GHI-CBP plan — high-volume source of OON disputes for retirees. NY DFS oversight; ConnectiCare is the Connecticut subsidiary.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Complement Inhibitor
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- EmblemHealth's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- HIP HMO referral denials
- GHI PPO out-of-network reductions (NYC municipal employee plan)
- Behavioral health prior auth
- Specialty drug PA
ECULIZUMAB (Soliris)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring ravulizumab (longer-acting) within class
- Meningococcal vaccination not documented (REMS requirement)
- Indication restriction (PNH vs aHUS vs gMG vs NMOSD)
- Site-of-care reduction
Brand: Soliris. C5 complement inhibitor. FDA-approved for PNH, aHUS, generalized myasthenia gravis (anti-AChR+), and NMOSD (anti-AQP4+). REMS-restricted (meningococcal infection risk). Plans increasingly steering to ravulizumab (Ultomiris).
Manufacturer patient-assistance program: Alexion OneSource — relevant when an EmblemHealth denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.emblemhealth.com/providers) with the same packet plus an applicable, current clinical source supporting ECULIZUMAB (Soliris)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal an EmblemHealth denial on DenialHelp.
Contact EmblemHealth
- Provider portal: https://www.emblemhealth.com/providers
Frequently asked questions
What documentation does EmblemHealth need for ECULIZUMAB (Soliris) prior auth?
EmblemHealth's typical PA packet for ECULIZUMAB (Soliris): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Complement Inhibitor, expect clinical-criteria documentation specific to this class.
What's the turnaround time at EmblemHealth?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for ECULIZUMAB (Soliris) at EmblemHealth?
Preparation scenarios to check against the current notice and policy include: HIP HMO referral denials; GHI PPO out-of-network reductions (NYC municipal employee plan); Behavioral health prior auth. These are not measured frequency claims. For ECULIZUMAB (Soliris), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
How do I prep for a peer-to-peer with EmblemHealth on ECULIZUMAB (Soliris)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the ECULIZUMAB (Soliris) PA packet
Open ApprovalHelp — generate a ECULIZUMAB (Soliris) prior-auth packet tailored to EmblemHealth's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com